Podcasts

Professor Ed Vital discusses two key publications covered on the Lupus Forum in December. his podcast reviews data from a randomised, double-blind, placebo-controlled Phase Ib/IIa trial of the anti-CD38 monoclonal antibody CM313 in adults with systemic lupus erythematosus (SLE), focusing on safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy. The episode also examines predictors of damage accrual by organ domain in SLE, highlighting factors associated with long-term disease outcomes.

Professor Richard Furie and Doctor Guillermo J. Pons-Estel review two key publications covered on the Lupus Forum in November. This podcast reports data from a multicentre, randomised, double-blind, placebo-controlled trial evaluating low-dose belimumab in patients with systemic lupus erythematosus (SLE), with a focus on disease flare prevention. The episode also reports findings on the efficacy and safety of allogeneic CD19 CAR NK-cell therapy in SLE, based on a case series conducted in China in patients with mild disease activity.

Join Professor Ed Vital, Dr Guillermo J. Pons-Estel, Professor Richard Furie and Professor Chris Edwards on the Lupus Forum for their discussion of the recent webinar “Early use of advanced therapies in lupus”. Watch them discuss key highlights from the webinar, including limitations of SoC, insights from clinical trials and strategies for early intervention with advanced therapies.

Professor Vibeke Strand highlights the emerging treatments in SLE and LN. This podcast reports the efficacy and safety results of a Phase 3 trial of telitacicept at a dose of 160mg weekly as compared with PBO in Chinese persons with active SLE. The efficacy and safety of SC secukinumab 300mg compared with PBO, in combination with the SoC, in patients with active LN is also reported.

Join Professor Chris Edwards and Dr Alice Mason as they discuss EULAR recommendations for a core dataset in SLE and the efficacy and safety of upadacitinib as a monotherapy or in combination with elsubrutinib for SLE. This podcast provides a valuable framework for guiding therapeutic decisions in SLE and also supporting clinical care and translational/observational research.

Professor Eric Morand and Professor Rangi Kandane-Rathnayake discuss the therapeutic strategies and emerging treatments in SLE and LN. This podcast provides a valuable framework for guiding therapeutic decisions for rare SLE manifestations where the available recommendations might be insufficient or inapplicable. The efficacy, PK and safety of iscalimab versus placebo as add-on to SoC therapy in patients with biopsy-proven active proliferative LN is also reported.